TAKEDA ACQUIRES RIGHTS TO DPP4 INHIBITORS GRANTED TO

Takeda Pharmaceutical Company Limited and PPD, Inc. (Nasdaq: PPDI - News) today announced an agreement in which Takeda acquired the development and marketing rights to all dipeptidyl peptidase IV (DPP4) inhibitors previously granted to PPD under an agreement between PPD and Syrrx, Inc. Takeda acquired Syrrx, Inc., now known as Takeda San Diego, Inc., in March 2005. Under the new agreement, Takeda, through Takeda San Diego, acquired all the remaining rights to develop and commercialize the DPP4 inhibitors, which rights had been shared by PPD and Takeda San Diego under the collaboration agreement dated November 19, 2003.

Yahoo News (http://biz.yahoo.com/prnews/050713/cgw046.html?.v=20)